Weekly healthcare intelligenceRegulation · Enforcement · Government payersAll editions →

All articles and reminders · Compliance Sweep

Published November 4, 2026 · Reporting window October 25–31, 2026, Pacific. Later developments are labelled. Source coverage is incomplete; the complete reports describe the limitations.

All articlesSearch this edition →
Compliance Sweep: complete report →

17 articles and reminders, grouped by category.

Compliance Sweep

Higher-priority matters

Patient care & rights 4 articles and reminders

Patient care & rightsCompliance SweepNew in this edition

Medically frail court opinion

On October 29, 2026, the District of Massachusetts concluded that an added limitation requiring impairment of community engagement for certain medically frail determinations was contrary to law. The court rejected the states’ arbitrary-and-capricious challenges to the 12-month claims and encounter-data lookback and limits on self-attestation. The opinion discusses vacatur, a permanent injunction and a six-month enforcement stay for plaintiff states, while its formal order grants and denies the cross-motions in part without specifying those terms. The operative relief, timing, geographic and party scope, and later proceedings remain unverified.

Medium priority · Nov 4, 2026 editionRead story →

Patient care & rightsCompliance SweepNew in this edition

OIG patient-engagement safe-harbor cap

OIG’s annual inflation update, marked October 28, 2026, lists a $646 cap for 2027, up from $623 for 2026. The cap is one condition of the patient-engagement safe harbor and applies to the annual aggregate retail value of tools and supports furnished to a patient by a value-based enterprise participant; other safe-harbor conditions also apply.

Medium priority · Nov 4, 2026 editionRead story →

Patient care & rightsCompliance SweepNew in this edition

FTC healthcare marketing warning template

An FTC warning-letter template concerning marketing, advertising and lead generation for healthcare-related products, including healthcare plans, is labeled “Date Sent” October 29, 2026 on its official landing page. The template says some marketing and lead-generation practices may violate law and discusses potential misrepresentations about coverage, costs or incentives, impersonation and telemarketing; it recommends reviewing relevant practices. It expressly states that the letter is not a conclusion that a recipient engaged in illegal conduct. Organizations involved in health-plan marketing or lead generation can compare their practices with applicable requirements.

Medium priority · Nov 4, 2026 editionRead story →

Patient care & rightsCompliance SweepNew in this edition

California proposes permanent hospice agency regulations

California’s regulatory notice describes a proposal to permanently adopt Title 22 hospice agency requirements addressing licensure, management qualifications, service areas and oversight. Written comments must be received by December 14, 2026; a public hearing is scheduled for December 15, 10 a.m. to noon Pacific. The separate emergency regulations are already in effect; the proposed permanent adoption remains a rulemaking action.

Medium priority · Nov 4, 2026 editionRead story →

Payment & health plan rules 1 articles and reminders

Payment & health plan rulesCompliance SweepNew in this edition

OPO conditions for coverage

CMS’s October 30 fact sheet describes a final rule revising organ procurement organization conditions for coverage, including adverse-event, research-organ record, designation, competition and transition provisions. The rule retains the three-tier recertification framework; an OPO losing a competition to retain a tier 2 donation service area faces nonrenewal of its agreement for designation to that donation service area, not automatic decertification of the entire OPO. Post-window publication update: CMS published CMS-3409-F on November 3, 2026, at 91 FR 69390–69444. The published rule states an effective date of January 4, 2027. Publication does not establish any particular organization’s compliance with the rule.

Medium priority · Nov 4, 2026 editionRead story →

Governance & business operations 10 articles and reminders

Governance & business operationsCompliance SweepNew in this edition

HHS Section 504 public-inspection rule

HHS filed a final rule for public inspection on October 30, 2026, concerning its Section 504 disability regulations for programs and activities receiving HHS financial assistance. The retained text would revise 45 CFR 84.4(g) to state HHS’s interpretation that the statutory exclusion for gender identity disorders not resulting from physical impairments includes gender dysphoria not resulting from physical impairments. Post-window publication update: HHS published the final rule on November 3, 2026, at 91 FR 69207–69223. The published rule states an effective date of January 4, 2027. HHS’s interpretation does not resolve the effect of court orders or other applicable federal and state protections in a particular case.

Medium priority · Nov 4, 2026 editionRead story →

Governance & business operationsCompliance SweepNew in this edition

HHS draft 503A peptide compounding policy

On October 30, HHS announced a draft enforcement-discretion policy concerning certain peptide bulk drug substances used in section 503A compounding while the applicable bulk-substances list is developed. The notice requests written comments within two weeks after publication. HHS says the draft does not establish rights and is not binding on HHS or the public. The notice does not establish blanket permission to compound every peptide; the named substances, conditions and current status require review.

Medium priority · Nov 4, 2026 editionRead story →

Governance & business operationsCompliance SweepNew in this edition

Centanafadine Schedule III interim rule

DEA issued an interim final rule placing centanafadine, including its salts, isomers and salts of isomers where possible, in Schedule III effective October 30, 2026. The rule requests comments by November 30. The rule's actual provisions and applicability should be reviewed for an organization's circumstances; this summary does not assert a particular patient's treatment or a universal prescribing change.

Medium priority · Nov 4, 2026 editionRead story →

Governance & business operationsCompliance SweepNew in this edition

HTI-5 certification criteria

ONC’s HTI-5 final rule, published October 28, 2026, removes 14 and revises seven of the 60 health IT certification criteria it describes as currently in effect, while retaining 39 unchanged. ONC says proposals not addressed in the final rule remain under consideration. Removing a certification criterion does not itself require vendors to remove a feature or erase other applicable obligations. The published rule is effective December 28, 2026, except amendatory instructions 7, 10 and 12, which are effective January 1, 2027.

Medium priority · Nov 4, 2026 editionRead story →

Governance & business operationsCompliance SweepNew in this edition

FDA early alert: Medline beds and accessories

FDA’s device-safety listing identifies an October 29 early alert concerning Medline-brand beds and associated products. A subsequently viewed FDA alert describes electrical overheating and fire risks as well as separate entrapment or asphyxiation risks associated with accessories, a pendant or loose rails. FDA says all Medline-brand beds and associated components are affected, including home-care, bariatric and long-term-care beds. FDA reports that covered beds, rails, mattresses and accessories may remain in use under the updated instructions until the bed is repaired or replaced. The later-observed precautions include unplugging beds except when needed for repositioning, avoiding extension cords and, whenever possible, having a second person assist with use and movement. FDA advises against repairing, modifying or altering a bed except through the specified Medline-authorized process.

High priority · Nov 4, 2026 editionRead story →

Governance & business operationsCompliance SweepNew in this edition

FDA early alert: selected B. Braun Dialog+ bloodlines

FDA’s device-safety listing identifies an October 27 early alert for selected B. Braun Streamline Bloodline Sets for the Dialog+ hemodialysis system. The later-viewed FDA alert identifies model SL-2010M2096 and lots A2600099, A2600128 and A2600136. FDA describes a potentially inadequately bonded dialyzer connector that could detach or leak during priming or dialysis, risking blood loss or interrupted treatment. FDA says to ensure all users are informed and to identify and quarantine affected devices. Its description of B. Braun’s October 20 letter says to inform users, have distributors forward the notice to consignees, determine inventory, stop use, quarantine and return affected product to the manufacturer.

High priority · Nov 4, 2026 editionRead story →

Governance & business operationsCompliance SweepNew in this edition

FDA recall: selected HemosIL HIT assay lots

FDA’s device-safety listing identifies an October 30 confirmed recall of selected lots of HemosIL AcuStar HIT-IgG(PF4-H), used with other information to aid assessment of heparin-induced thrombocytopenia. In the FDA page captured November 2, part 0009800127 is associated with lots B40005 and B38062, and part 0009802028 with lots B40006 and B38063. FDA describes a negative bias of 20–35% that may produce results below the 1.00 U/mL cutoff and be interpreted as HIT IgG antibody negative. The page also contains internally inconsistent error-type wording; its title and device-use description use different assay terminology.

High priority · Nov 4, 2026 editionRead story →

Governance & business operationsCompliance SweepNew in this edition

EEOC criminal-record guidance

The EEOC announced October 29 that the Commission voted October 28 to rescind its 2012 enforcement guidance on the use of arrest and conviction records in employment decisions under Title VII, effective immediately. The agency says Title VII continues to prohibit unlawful discrimination. Healthcare employers should consult employment and licensing counsel about applicable requirements before changing background-check practices. The rescission instrument and state-specific requirements have not been independently reviewed here.

Medium priority · Nov 4, 2026 editionRead story →

Governance & business operationsCompliance SweepNew in this edition

FDA clarifies safety steps for StatStrip Gen 2.0 glucose meters

FDA says prior patient or quality-control information can remain on the affected meter screen and, if accepted, assign a glucose result to the wrong record. The agency says users with an alternative meter should stop using the affected meter until it is updated. Where no alternative is available, users should follow the manufacturer’s interim safeguards, including the identification checks described in the FDA communication. FDA reported one serious injury and no deaths as of October 5.

High priority · Nov 4, 2026 editionRead story →

More matters and continuing watch

Patient care & rights 1 articles and reminders

Governance & business operations 1 articles and reminders

Privacy preferences

Where enabled for this site, Cloudflare Web Analytics can send page-use and performance measurements to Cloudflare. This panel provides information and does not turn analytics on or off.

This panel stores no tracking choice and does not change your tool saves, screening, resets, reports or exports. Other sites have separate settings.

Read Privacy & Cookies